Linking vitamin D deficiency to inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 10, 2013, Pages 2245-2256

  Palmer, Matthew T ^a   Weaver, Casey T ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Ulcerative colitis; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; 7 DEHYDROCHOLESTEROL; CALCIUM; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHOLESTANETRIOL 26 MONOOXYGENASE; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 27B1; CYTOCHROME P450 2R1; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MELANIN; PLACEBO; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; BIOAVAILABILITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNODEFICIENCY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ASSOCIATION; ENTERITIS; EPIDEMIOLOGICAL DATA; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; INDUSTRIALIZATION; INNATE IMMUNITY; INTESTINE EPITHELIUM; INTESTINE FLORA; LATITUDE; MULTIPLE SCLEROSIS; NONHUMAN; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; RISK FACTOR; SEASONAL VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN PIGMENTATION; SMOKING; SUN EXPOSURE; TH1 CELL; TH17 CELL; TREATMENT OUTCOME; ULCERATIVE COLITIS; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84884582015     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828a3b6f     Document Type: Review

References (195)

1. Molodecky NA, Panaccione R, Ghosh S, et al. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:1792-1799.
2. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57:1185-1191.
3. Bernstein CN. Assessing environmental risk factors affecting the inflammatory bowel diseases: a joint workshop of the Crohn's & Colitis Foundations of Canada and the USA. Inflamm Bowel Dis. 2008;14: 1139-1146.
4. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010;6:339-346.
5. Shores DR, Binion DG, Freeman BA, et al. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:2192-2204.
6. Hochberg Z. Rickets-past and present. Introduction. Endocr Dev. 2003; 6:1-13.
7. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
8. Norton HL, Kittles RA, Parra E, et al. Genetic evidence for the convergent evolution of light skin in Europeans and East Asians. Mol Biol Evol. 2007;24:710-722.
9. Lamason RL, Mohideen MA, Mest JR, et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science. 2005; 310:1782-1786.
10. Gibbons A. American Association of Physical Anthropologists meeting. European skin turned pale only recently, gene suggests. Science. 2007; 316:364.
11. Diamond J. Evolutionary biology: geography and skin colour. Nature. 2005;435:283-284.
12. Jablonski NG, Chaplin G. Colloquium paper: human skin pigmentation as an adaptation to UV radiation. Proc Natl Acad Sci U S A. 2010;107 (suppl 2):8962-8968.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
14. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab. 2012;97:1146-1152.
15. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008; 29:726-776.
16. Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am. 2010;39:255-269, table of contents.
17. Adams JS, Chen H, Chun R, et al. Substrate and enzyme trafficking as a means of regulating 1,25-dihydroxyvitamin D synthesis and action: the human innate immune response. J Bone Miner Res. 2007;22(suppl 2): V20-V24.
18. Bikle DD. Vitamin D and the skin. J Bone Miner Metab. 2010;28: 117-130.
19. Henry HL, Norman AW. Vitamin D: two dihydroxylated metabolites are required for normal chicken egg hatchability. Science. 1978;201: 835-837.
20. Ornoy A, Goodwin D, Noff D, et al. 24, 25-dihydroxyvitamin D is a metabolite of vitamin D essential for bone formation. Nature. 1978; 276:517-519.
21. Harant H, Spinner D, Reddy GS, et al. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J Cell Biochem. 2000;78:112-120.
22. Need AG, Horowitz M, Morris HA, et al. Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women. Am J Clin Nutr. 2000;71:1577-1581.
23. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003;88: 185-191.
24. Rejnmark L, Vestergaard P, Heickendorff L, et al. Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis D. Eur J Endocrinol. 2008;158:571-576.
25. Need AG, O'Loughlin PD, Morris HA, et al. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res. 2008;23:1859-1863.
26. Hewison M, Burke F, Evans KN, et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103:316-321.
27. Hewison M, Freeman L, Hughes SV, et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol. 2003;170:5382-5390.
28. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770-1773.
29. Adams JS, Ren S, Liu PT, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182:4289-4295.
30. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285: 2227-2231.
31. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188:2127-2135.
32. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996;239:131-137.
33. El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. 2011;56:825-829.
34. Harries AD, Brown R, Heatley RV, et al. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut. 1985;26: 1197-1203.
35. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol. 2004;39: 527-533.
36. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35:308-316.
37. Fu YT, Chatur N, Cheong-Lee C, et al. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci. 2012;57:2144-2148.
38. Levin AD, Wadhera V, Leach ST, et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci. 2011;56:830-836.
39. Lo CW, Paris PW, Clemens TL, et al. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr. 1985;42:644-649.
40. Farraye FA, Nimitphong H, Stucchi A, et al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. Inflamm Bowel Dis. 2011;17: 2116-2121.
41. Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53:1129-1136.
42. Fritsche J, Mondal K, Ehrnsperger A, et al. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood. 2003;102:3314-3316.
43. Holowaychuk MK, Birkenheuer AJ, Li J, et al. Hypocalcemia and hypovitaminosis D in dogs with induced endotoxemia. J Vet Intern Med. 2012;26:244-251.
44. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359:248-252.
45. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-1163.
46. Gannage-Yared MH, Chemali R, Yaacoub N, et al. Hypovitaminosis D in a sunny country: relation to lifestyle and bone markers. J Bone Miner Res. 2000;15:1856-1862.
47. Maddah M, Sharami SH, Neyestani TR. Vitamin D insufficiency among postmenopausal women in urban and rural areas in Guilan, Northern Iran. J Nutr Elder. 2009;28:386-393.
48. Heere C, Skeaff CM, Waqatakirewa L, et al. Serum 25-hydroxyvitamin D concentration of Indigenous-Fijian and Fijian-Indian women. Asia Pac J Clin Nutr. 2010;19:43-48.
49. Chailurkit LO, Aekplakorn W, Ongphiphadhanakul B. Regional variation and determinants of vitamin D status in sunshine-abundant Thailand. BMC Public Health. 2011;11:853.
50. Bailey BA, Manning T, Peiris AN. The impact of living in rural and urban areas: vitamin D and medical costs in veterans. J Rural Health. 2012;28: 356-363.
51. Choi EY. 25(OH)D status and demographic and lifestyle determinants of 25(OH)D among Korean adults. Asia Pac J Clin Nutr. 2012;21:526-535.
52. Nguyen HT, von Schoultz B, Nguyen TV, et al. Vitamin D deficiency in northern Vietnam: prevalence, risk factors and associations with bone mineral density. Bone. 2012;51:1029-1034.
53. Nichols EK, Khatib IM, Aburto NJ, et al. Vitamin D status and determinants of deficiency among non-pregnant Jordanian women of reproductive age. Eur J Clin Nutr. 2012;66:751-756.
54. Mims FM III. Significant reduction of UVB caused by smoke from biomass burning in Brazil. Photochem Photobiol. 1996;64:814-816.
55. Agarwal KS, Mughal MZ, Upadhyay P, et al. The impact of atmospheric pollution on vitamin D status of infants and toddlers in Delhi, India. Arch Dis Child. 2002;87:111-113.
56. Manicourt DH, Devogelaer JP. Urban tropospheric ozone increases the prevalence of vitamin D deficiency among Belgian postmenopausal women with outdoor activities during summer. J Clin Endocrinol Metab. 2008;93:3893-3899.
57. Hosseinpanah F, Pour SH, Heibatollahi M, et al. The effects of air pollution on vitamin D status in healthy women: a cross sectional study. BMC Public Health. 2010;10:519.
58. Baiz N, Dargent-Molina P, Wark JD, et al. Gestational exposure to urban air pollution related to a decrease in cord blood vitamin D levels. J Clin Endocrinol Metab. 2012;97:4087-4095.
59. McKinley A, Janda M, Auster J, et al. In vitro model of vitamin D synthesis by UV radiation in an Australian urban environment. Photochem Photobiol. 2011;87:447-451.
60. Scragg R, Camargo CA Jr. Frequency of leisure-time physical activity and serum 25-hydroxyvitamin D levels in the US population: results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2008;168:577-586; discussion 587-591.
61. Economou M, Pappas G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709-720.
62. Malaty HM, Fan X, Opekun AR, et al. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr. 2010;50:27-31.
63. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
64. Soon IS, Molodecky NA, Rabi DM, et al. The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterol. 2012;12:51.
65. Kaplan GG, Hubbard J, Korzenik J, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol. 2010;105:2412-2419.
66. Beamish LA, Osornio-Vargas AR, Wine E. Air pollution: an environmental factor contributing to intestinal disease. J Crohns Colitis. 2011;5: 279-286.
67. Ananthakrishnan AN, McGinley EL, Binion DG, et al. Ambient air pollution correlates with hospitalizations for inflammatory bowel disease: an ecologic analysis. Inflamm Bowel Dis. 2011;17:1138-1145.
68. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88:1519-1527.
69. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169:626-632.
70. Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807-1820.
71. Luxwolda MF, Kuipers RS, Kema IP, et al. Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. Br J Nutr. 2012;108:1557-1561.
72. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42; quiz e30.
73. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72:690-693.
74. Drincic AT, Armas LA, Van Diest EE, et al. Volumetric dilution, rather than sequestration best explains the low vitamin d status of obesity. Obesity (Silver Spring). 2012;20:1444-1448.
75. Yarur AJ, Deshpande AR, Pechman DM, et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741-747.
76. Gerasimidis K, McGrogan P, Edwards CA. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet. 2011;24:313-326.
77. Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:2162-2168.
78. Mendall MA, Gunasekera AV, John BJ, et al. Is obesity a risk factor for Crohn's disease? Dig Dis Sci. 2011;56:837-844.
79. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30:771-777.
80. Weisberg P, Scanlon KS, Li R, et al. Nutritional rickets among children in the United States: review of cases reported between 1986 and 2003. Am J Clin Nutr. 2004;80(6 suppl):1697S-1705S.
81. Veluswamy H, Suryawala K, Sheth A, et al. African-American inflammatory bowel disease in a Southern U.S. health center. BMC Gastroenterol. 2010;10:104.
82. Kenny EE, Pe'er I, Karban A, et al. A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet. 2012;8:e1002559.
83. Jablonski NG, Chaplin G. The evolution of human skin coloration. J Hum Evol. 2000;39:57-106.
84. Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects Med. 2008;29:453-461.
85. Abakar-Mahamat A, Filippi J, Pradier C, et al. Incidence of inflammatory bowel disease in Corsica from 2002 to 2003. Gastroenterol Clin Biol. 2007;31:1098-1103.
86. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11:134-147.
87. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991;100:143-149.
88. Tragnone A, Hanau C, Bazzocchi G, et al. Epidemiological characteristics of inflammatory bowel disease in Bologna, Italy-incidence and risk factors. Digestion. 1993;54:183-188.
89. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690-697.
90. Armitage EL, Aldhous MC, Anderson N, et al. Incidence of juvenileonset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology. 2004;127:1051-1057.
91. Nerich V, Monnet E, Etienne A, et al. Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis. 2006;12:218-226.
92. Nerich V, Monnet E, Weill A, et al. Fine-scale geographic variations of inflammatory bowel disease in France: correlation with socioeconomic and house equipment variables. Inflamm Bowel Dis. 2010;16:813-821.
93. Khalili H, Huang ES, Ananthakrishnan AN, et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012;61:1686-1692.
94. Sonnenberg A, Genta RM. Geographic distributions of microscopic colitis and inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2012;18:2288-2293.
95. Kimlin MG, Olds WJ, Moore MR. Location and vitamin D synthesis: is the hypothesis validated by geophysical data? J Photochem Photobiol B. 2007;86:234-239.
96. Freisling H, Fahey MT, Moskal A, et al. Region-specific nutrient intake patterns exhibit a geographical gradient within and between European countries. J Nutr. 2010;140:1280-1286.
97. Hagenau T, Vest R, Gissel TN, et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int. 2009;20:133-140.
98. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7: 439-443.
99. Kuchuk NO, van Schoor NM, Pluijm SM, et al. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res. 2009;24:693-701.
100. Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85:860-868.
101. Shoben AB, Kestenbaum B, Levin G, et al. Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study. Am J Epidemiol. 2011;174:1363-1372.
102. Don BA, Goldacre MJ. Absence of seasonality in emergency hospital admissions for inflammatory bowel disease. Lancet. 1984;2:1156-1157.
103. Myszor M, Calam J. Seasonality of ulcerative colitis. Lancet. 1984;2: 522-523.
104. Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse? Gut. 1990;31:179-183.
105. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991;100:350-358.
106. Tysk C, Jarnerot G. Seasonal variation in exacerbations of ulcerative colitis. Scand J Gastroenterol. 1993;28:95-96.
107. Sonnenberg A, Jacobsen SJ, Wasserman IH. Periodicity of hospital admissions for inflammatory bowel disease. Am J Gastroenterol. 1994; 89:847-851.
108. Bellaiche G, Beaugerie L, Carbonnel F, et al. The clinical activity of Crohn's disease in the Paris area is maximal in the spring [Article in French]. Ann Gastroenterol Hepatol (Paris). 1995;31:150-153.
109. Moum B, Aadland E, Ekbom A, et al. Seasonal variations in the onset of ulcerative colitis. Gut. 1996;38:376-378.
110. Zeng L, Anderson FH. Seasonal change in the exacerbations of Crohn's disease. Scand J Gastroenterol. 1996;31:79-82.
111. Karamanolis DG, Delis KC, Papatheodoridis GV, et al. Seasonal variation in exacerbations of ulcerative colitis. Hepatogastroenterology. 1997; 44:1334-1338.
112. Vergara M, Fraga X, Casellas F, et al. Seasonal influence in exacerbations of inflammatory bowel disease. Rev Esp Enferm Dig. 1997;89:357-366.
113. Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004;126:665-673.
114. Auslander JN, Lieberman DA, Sonnenberg A. Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2005;100:2233-2238.
115. Aratari A, Papi C, Galletti B, et al. Seasonal variations in onset of symptoms in Crohn's disease. Dig Liver Dis. 2006;38:319-323.
116. Soncini M, Triossi O, Leo P, et al. Seasonal patterns of hospital treatment for inflammatory bowel disease in Italy. Digestion. 2006;73:1-8.
117. Bai A, Guo Y, Shen Y, et al. Seasonality in flares and months of births of patients with ulcerative colitis in a Chinese population. Dig Dis Sci. 2009;54:1094-1098.
118. Romberg-Camps MJ, Hesselink-van de Kruijs MA, Schouten LJ, et al. Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991-2002: incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis. 2009;3:115-124.
119. Bours PH, Wielders JP, Vermeijden JR, et al. Seasonal variation of serum 25-hydroxyvitamin D levels in adult patients with inflammatory bowel disease. Osteoporos Int. 2011;22:2857-2867.
120. Sonnenberg A. Seasonal variation of enteric infections and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:955-959.
121. Sonnenberg A. Seasonal variation of enteric infections and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:809.
122. Basaranoglu M. Symptom date is better than the endoscopic diagnosis date in seasonal variation studies in IBD. Am J Gastroenterol. 2006;101: 2668-2669.
123. McCullough ML, Weinstein SJ, Freedman DM, et al. Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172:21-35.
124. Al-Daghri NM, Al-Attas OS, Alokail MS, et al. Increased vitamin D supplementation recommended during summer season in the gulf region: a counterintuitive seasonal effect in vitamin D levels in adult, overweight and obese Middle Eastern residents. Clin Endocrinol (Oxf). 2012;76: 346-350.
125. James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond). 2008;32(suppl 7):S120-S126.
126. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
127. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat Rev Immunol. 2011;11:584-596.
128. Albert E, Walker J, Thiesen A, et al. cis-Urocanic acid attenuates acute dextran sodium sulphate-induced intestinal inflammation. PLoS One. 2010;5:e13676.
129. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut. 2000;47:211-214.
130. Martin K, Radlmayr M, Borchers R, et al. Candidate genes colocalized to linkage regions in inflammatory bowel disease. Digestion. 2002;66:121-126.
131. Dresner-Pollak R, Ackerman Z, Eliakim R, et al. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test. 2004;8:417-420.
132. Naderi N, Farnood A, Habibi M, et al. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1816-1822.
133. Hughes DJ, McManus R, Neary P, et al. Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case-control study. Eur J Gastroenterol Hepatol. 2011;23:807-812.
134. Pei FH, Wang YJ, Gao SL, et al. Vitamin D receptor gene polymorphism and ulcerative colitis susceptibility in Han Chinese. J Dig Dis. 2011;12: 90-98.
135. Noble CL, McCullough J, Ho W, et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:588-596.
136. Bentley RW, Keown D, Merriman TR, et al. Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males. Aliment Pharmacol Ther. 2011;33:855-856.
137. Eloranta JJ, Wenger C, Mwinyi J, et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics. 2011;21:559-564.
138. Uitterlinden AG, Ralston SH, Brandi ML, et al. The association between common vitamin D receptor gene variations and osteoporosis: a participantlevel meta-analysis. Ann Intern Med. 2006;145:255-264.
139. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
140. Cantorna MT, Munsick C, Bemiss C, et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648-2652.
141. Zhu Y, Mahon BD, Froicu M, et al. Calcium and 1 alpha,25- dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217-224.
142. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17:2386-2392.
143. Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology. 2006;117:310-318.
144. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007;8:5.
145. Liu N, Nguyen L, Chun RF, et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology. 2008;149:4799-4808.
146. Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology. 2010;151:2423-2432.
147. Daniel C, Radeke HH, Sartory NA, et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther. 2006;319: 622-631.
148. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324:23-33.
149. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19:1067-1077.
150. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis. 2009;15: 1656-1662.
151. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377-383.
152. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002;288:358-362.
153. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362-381.
154. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
155. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008;294:G208-G216.
156. Netea MG, Joosten LA. A NOD for autophagy. Nat Med. 2010;16: 28-30.
157. Zilbauer M, Jenke A, Wenzel G, et al. Expression of human beta-defensins in children with chronic inflammatory bowel disease. PLoS One. 2010; 5:e15389.
158. Liu PT, Schenk M, Walker VP, et al. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One. 2009;4:e5810.
159. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe. 2009;6:231-243.
160. Campbell GR, Spector SA. Hormonally active vitamin D3 (1alpha, 25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem. 2011;286: 18890-18902.
161. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med. 2011;3:104ra102.
162. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
163. Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis. 2010;16:507-511.
164. Maynard CL, Weaver CT. Intestinal effector T cells in health and disease. Immunity. 2009;31:389-400.
165. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314:1461-1463.
166. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
167. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135: 1130-1141.
168. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319-1323.
169. Roers A, Siewe L, Strittmatter E, et al. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med. 2004;200:1289-1297.
170. Palmer MT, Lee YK, Maynard CL, et al. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem. 2011;286:997-1004.
171. Chang JH, Cha HR, Lee DS, et al. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One. 2010;5:e12925.
172. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptordependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:6800-6805.
173. Cotsapas C, Hafler DA. Immune-mediated disease genetics: the shared basis of pathogenesis. Trends Immunol. 2012;34:22-26.
174. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9:599-612.
175. Bahlo M, Booth DR, Broadley SA, et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824-828.
176. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-219.
177. Higuchi LM, Khalili H, Chan AT, et al. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107:1399-1406.
178. Odoardi F, Sie C, Streyl K, et al. T cells become licensed in the lung to enter the central nervous system. Nature. 2012;488:675-679.
179. Ransohoff RM. Immunology: licensed in the lungs. Nature. 2012;488: 595-596.
180. Dong J, Hu Z, Wu C, et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet. 2012;44:895-899.
181. Edfeldt K, Liu PT, Chun R, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci U S A. 2010;107:22593-22598.
182. Matsunawa M, Amano Y, Endo K, et al. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Toxicol Sci. 2009;109:50-58.
183. Gerde P, Muggenburg BA, Lundborg M, et al. Respiratory epithelial penetration and clearance of particle-borne benzo[a]pyrene. Res Rep Health Eff Inst. 2001;101:5-25; discussion 27-32.
184. Libert C. Inflammation: a nervous connection. Nature. 2003;421: 328-329.
185. Yerger VB, Malone RE. Melanin and nicotine: a review of the literature. Nicotine Tob Res. 2006;8:487-498.
186. King G, Yerger VB, Whembolua GL, et al. Link between facultative melanin and tobacco use among African Americans. Pharmacol Biochem Behav. 2009;92:589-596.
187. Cho YH, Jeong DW, Seo SH, et al. Changes in skin color after smoking cessation. Korean J Fam Med. 2012;33:105-109.
188. Diaz-Gomez NM, Mendoza C, Gonzalez-Gonzalez NL, et al. Maternal smoking and the vitamin D-parathyroid hormone system during the perinatal period. J Pediatr. 2007;151:618-623.
189. Pasco JA, Henry MJ, Nicholson GC, et al. Behavioural and physical characteristics associated with vitamin D status in women. Bone. 2009; 44:1085-1091.
190. Ardawi MS, Sibiany AM, Bakhsh TM, et al. High prevalence of vitamin D deficiency among healthy Saudi Arabian men: relationship to bone mineral density, parathyroid hormone, bone turnover markers, and lifestyle factors. Osteoporos Int. 2012;23:675-686.
191. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999;53: 920-926.
192. Morabia A, Bernstein MS, Antonini S. Smoking, dietary calcium and vitamin D deficiency in women: a population-based study. Eur J Clin Nutr. 2000;54:684-689.
193. Cutillas-Marco E, Fuertes-Prosper A, Grant WB, et al. Vitamin D deficiency in South Europe: effect of smoking and aging. Photodermatol Photoimmunol Photomed. 2012;28:159-161.
194. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010; 376:180-188.
195. Lee YK, Turner H, Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity. 2009;30:92-107.